Site Members can sign up for company wide alerts
Investigation Overview
December 17, 2013 (Update) -- On December 10, 2013, Avanir Pharmaceuticals Inc reported financial results for the three and twelve-months ended September 30, 2013 and announced results for phase II PRIME Study. Avanir Pharmaceuticals said that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic ...
You must register (for free) or login to view the entire investigation.